Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
03 avr. 2024 07h30 HE
|
Mereo BioPharma Group plc
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
27 mars 2024 16h01 HE
|
Mereo BioPharma Group plc
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively ...
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
05 mars 2024 07h30 HE
|
Mereo BioPharma Group plc
LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
08 janv. 2024 07h00 HE
|
Mereo BioPharma Group plc
Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q...
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
23 oct. 2023 16h01 HE
|
Mereo BioPharma Group plc
LONDON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an...
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
21 sept. 2023 07h00 HE
|
Mereo BioPharma Group plc
LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
07 sept. 2023 07h30 HE
|
Mereo BioPharma Group plc
LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Mereo BioPharma to Present at the Jefferies Healthcare Conference
31 mai 2023 07h00 HE
|
Mereo BioPharma Group plc
LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference
23 mai 2023 13h43 HE
|
Mereo BioPharma Group plc
LONDON, May 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases today announced...
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
08 mai 2023 12h46 HE
|
Mereo BioPharma Group plc
LONDON, May 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...